Johnson & Johnson and AbbVie both posted strong quarterly results but differ in dividend approach and business focus. J&J, a Dividend King with 64 years of raises, offers a modest 2.02% yield supported by diversified pharma and MedTech products. AbbVie pays a higher 2.78% yield but relies heavily on immunology drugs like Skyrizi and Rinvoq, facing risks from product concentration and recent acquisitions. Investors favor J&J for stable income and AbbVie for growth potential amid its post-Humira transition and strategic acquisitions.
Five US-listed Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, Colgate-Palmolive, and Lowe's—have announced dividend increases and reported earnings reflecting resilience amid economic challenges like tariffs and currency swings. Johns...
The iShares Core High Dividend ETF (HDV) relies heavily on energy and pharmaceutical sectors, with Exxon Mobil, Chevron, Johnson & Johnson, and AbbVie making up about 26% of its assets. Exxon and Johnson & Johnson are rated very safe due to strong ca...
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
Invesco's High Yield Equity Dividend Achievers ETF (PEY) uses a unique strategy by selecting stocks with at least 10 years of consecutive dividend growth before filtering for high yield. This approach avoids the pitfalls of pure yield-based ETFs that...
Johnson & Johnson shares trade near their 52-week high after a 55% rise, driven by strong revenue growth and promising drug sales. The company raised its full-year guidance, highlighting growth in key products like DARZALEX and TREMFYA. However, the ...
